In the Margins

Sequoia's Valeant bet hard lesson for investors

March 29, 2016

By MarketWatch

Sequoia Fund investors learned a hard lesson when the fund's investment in Valeant Pharmaceuticals went bad last year. "Bad doesn’t even begin to describe the situation for Sequoia, one of the most legendary mutual funds, which has seen its reputation torched by a bad bet on a controversial stock," writes MarketWatch's Chuck Jaffe in his latest column. Robert Goldfarb, CEO of adviser Ruane, Cunniff & Goldfarb and co-manager of Sequoia, resigned his fund duties last Wednesday. Read the original column from MarketWatch

 

 

Most Read

Top of the Agenda - Governance
Fund industry 'pioneer' Dorothy Berry dies

Long-serving independent director Dorothy Berry has died at 75. She was independent chair of Professionally Managed Portfolios and an independent director of PNC Funds who served ...

Top of the Agenda - Succession
Donohue joins two BNY Mellon Funds board groups

Andrew "Buddy" Donohue has joined two of the five BNY Mellon (formerly Dreyfus) mutual fund board groups led by long-serving independent Chairman Joseph DiMartino. Donohue resigned ...